Literature DB >> 3793725

Cholecystokinin-58 is the major circulating form of cholecystokinin in canine blood.

V E Eysselein, G A Eberlein, W H Hesse, M V Singer, H Goebell, J R Reeve.   

Abstract

Cholecystokinin-58 (CCK-58) is the largest and most abundant, biologically active form of cholecystokinin in canine intestinal mucosa. Despite the high amounts in mucosa, CCK-58 has not been detected in significant amounts in the circulation. The release of CCK-58 into the peripheral blood in response to an intraduodenal perfusion of sodium oleate (9.0 mmol h-1) was studied in seven conscious dogs. Plasma (50 ml) was obtained before and after endogenous stimulation by a newly developed method that prevents in vitro degradation of large cholecystokinins. The relative abundance of immunoreactive forms of CCK was studied by high pressure liquid chromatography (HPLC) which separated the gastrin and CCK forms. Column eluates were measured with an antibody which recognizes the intact carboxyl terminus of both gastrin and CCK. Cholecystokinin immunoreactivity increased over basal in plasma by 7 fmol/ml after intraduodenal perfusion with sodium oleate. The most abundant form of stimulated cholecystokinin immunoreactivity eluted on HPLC in the position of CCK-58 (63% of total immunoreactivity found). Since CCK-58 is biologically active and is the most abundant circulating form, it should play an important role in the physiology of cholecystokinin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3793725

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Role of cholecystokinin in pancreatic adaptation to massive enterectomy.

Authors:  P Watanapa; M Egan; P H Deprez; J Calam; C E Sarraf; M R Alison; R C Williamson
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Cholecystokinin-58 and cholecystokinin-8 exhibit similar actions on calcium signaling, zymogen secretion, and cell fate in murine pancreatic acinar cells.

Authors:  David N Criddle; David M Booth; Rajarshi Mukherjee; Euan McLaughlin; Gary M Green; Robert Sutton; Ole H Petersen; Joseph R Reeve
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-08       Impact factor: 4.052

Review 3.  Cholecystokinin and pancreatic cancer: the chicken or the egg?

Authors:  Jill P Smith; Travis E Solomon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

Review 4.  Biliary motility.

Authors:  P A Grace; G J Poston; R C Williamson
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

5.  Relationship of periodic pancreatic secretion and gallbladder contraction to plasma cholecystokinin in dogs.

Authors:  D F Magee; R F Murphy; S Naruse
Journal:  Ir J Med Sci       Date:  1988-08       Impact factor: 1.568

6.  Cholecystokinin-33 acutely attenuates food foraging, hoarding and intake in Siberian hamsters.

Authors:  Brett J W Teubner; Timothy J Bartness
Journal:  Peptides       Date:  2009-12-16       Impact factor: 3.750

7.  CCK-8 and CCK-58 differ in their effects on nocturnal solid meal pattern in undisturbed rats.

Authors:  Miriam Goebel-Stengel; Andreas Stengel; Lixin Wang; Gordon Ohning; Yvette Taché; Joseph R Reeve
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-08-08       Impact factor: 3.619

8.  Plasma concentrations of cholecystokinin, CCK-8, and CCK-33, 39 in rats, determined by a method based on enzyme digestion of gastrin before HPLC and RIA detection of CCK.

Authors:  A Lindén; M Carlquist; S Hansen; K Uvnäs-Moberg
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

9.  CCK-58 elicits both satiety and satiation in rats while CCK-8 elicits only satiation.

Authors:  Joost Overduin; James Gibbs; David E Cummings; Joseph R Reeve
Journal:  Peptides       Date:  2014-01-24       Impact factor: 3.750

Review 10.  Overview of exocrine pancreatic pathobiology.

Authors:  Arun R Pandiri
Journal:  Toxicol Pathol       Date:  2013-11-03       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.